5.35
-0.30
(-5.31%)
At close: January 10 at 9:35:50 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-48,691.00
-37,009.00
-43,483.00
-65,665.00
-35,019.00
Investing Cash Flow
-46,587.00
208.00
-23,964.00
66,062.00
-83,714.00
Financing Cash Flow
106,292.00
37,057.00
43,173.00
24,861.00
1,936.00
End Cash Position
16,064.00
14,811.00
14,555.00
38,829.00
13,571.00
Capital Expenditure
-1,877.00
-331.00
-130.00
-4,151.00
-1,336.00
Issuance of Capital Stock
87,901.00
37,389.00
69,428.00
24,030.00
1.00
Issuance of Debt
--
--
--
--
1,758.00
Repurchase of Capital Stock
--
--
-26,250.00
--
--
Free Cash Flow
-50,568.00
-37,340.00
-43,613.00
-69,816.00
-36,355.00
12/31/2020 - 8/28/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
41X.SG Ardelyx Inc
4.8570
-5.03%
BRNS Barinthus Biotherapeutics plc
1.0300
-9.65%
QLGN Qualigen Therapeutics, Inc.
4.2800
+2.64%
TENX Tenax Therapeutics, Inc.
6.24
-2.88%
AUTL Autolus Therapeutics plc
2.3600
-2.07%
APVO Aptevo Therapeutics Inc.
4.7900
-3.82%
PALI Palisade Bio, Inc.
1.9100
-4.98%
FBIO Fortress Biotech, Inc.
2.0300
-2.40%
TPST Tempest Therapeutics, Inc.
0.9494
-3.67%
LXRX Lexicon Pharmaceuticals, Inc.
0.7662
-10.86%